Your Contact. News Release Xxxxxxx Xxxxxx Phone +0-000-000-0000 March 30, 2015 Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy • Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono’s R&D technology portfolio in immuno-oncology • Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates Darmstadt, Germany, March 30, 2015 – Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation (NYSE:XON), today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono’s comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system’s natural ability to fight tumors. “The collaboration with Intrexon underlies Merck Serono’s focus on innovation, and enhances its R&D technology portfolio in immuno-oncology,” says Xxxxx Xxxxxx, President and CEO of Merck Serono. “Moreover, it showcases Merck Serono’s commitment to developing therapies that have the potential to significantly evolve the way cancer is treated.” CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, an immunological attack against the cancer cells is triggered. Utilizing Intrexon’s cell engineering techniques and RheoSwitch® platform, the collaboration aims to develop leading-edge products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. The agreement provides Merck Serono exclusive access to Intrexon’s proprietary and complementary suite of technologies to engineer T cells with optimized and inducible gene expression, as recently strengthened by a license agreement with the University of Texas MD Xxxxxxxx Cancer Center. Intrexon will be responsible for all platform and product developments until IND filing. Merck will nominate targets of interest for which CAR-T products will be developed. Merck will also lead the IND filing and pre-IND intera...
Your Contact. You will designate an individual who will have the responsibility to, and the authority of You, to make decisions concerning all matters relating to this Agreement (“Primary Contact”). You may change the individual designated as Primary Contact at any time by updating the information in the administration console for the Services.
Your Contact. Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name FINAL ENTRY TO BE RETURNED BEFORE 6 JUNE 2022 COUNTRY
Your Contact. Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name LATE REPLACEMENT FORM (LRF) TO BE SENT BY E-MAIL AFTER 6 JUNE 2022 AND BEFORE 20 JULY 2022 COUNTRY REPLACED MEMBER REPLACEMENT Rank Family Name Given Name Sport/ Function Rank Family Name Given Name Passport No. Your Contact Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name LATE REPLACEMENT FORM (LRF) AFTER 6 JUNE 2022 AND BEFORE 20 JULY 2022 COUNTRY FLIGHT AND TRAVEL INFORMATION DETAIL (Number of people per sport / city overview) FINAL DESTINATION ARRIVAL DEPARTURE FLIGHT (TRAIN) No. DATE TIME No. OF PEOPLE FLIGHT (TRAIN) No. DATE TIME No. OF PEOPLE Your Contact Rank/Name Phone Fax E-Mail Date Signature of Chief of Delegation Rank/Name 1Each Nation must bring 2 international referees for Volleyball Competitions (1 for Men and 1 for Women competition)
Your Contact. You must designate a contact person (“Your Contact”) with whom Vital-Sim will communicate in relation to Support. You must notify Vital-Sim of the contact details, and any changes to those contact details, for Your Contract including telephone and facsimile numbers and email addresses. You may change Your Contact at any time by giving Vital-Sim reasonable notice of such change. Your Contact must be trained in the use of the Software, familiar with the Documentation and devote any necessary time and effort to assist Vital-Sim in resolving Problems in accordance with this Agreement. You will be solely responsible for any costs or expenses You incur in performing Your obligations under this Agreement, including the cost of any telecommunications or internet access charges. Contacting Vital-Sim Your Contact can contact Vital-Sim by: telephoning 000-000-0000; sending an email to support@vital-sim; or using the support that may be available on Vital-Sim’s website. Excluded Services Support does not include: installation, training, configuration, customization or other services not expressly described in Section 0; help with any Problem caused by: Your use of the Licensed Materials other than in accordance with this Agreement; modifications or alterations to the Licensed Materials not made by Vital-Sim; use of the Licensed Materials in connection or combination with equipment, devices or software that are not specified in writing by Vital-Sim as being compatible with the Software; Your failure to implement any Patches or Updates that are made available to You or; Your failure to implement any New Release of the Software, if Vital-Sim has given You at least 180 days’ notice that it will no longer be supporting previous releases of the Software; or any Support provided by Vital-Sim, at Your request, which is outside Business Hours or at Your facilities, (together the “Excluded Services”). Vital-Sim may, but is under no obligation to, perform such Excluded Services for You upon receipt of a request to do so. Fees and Taxes
